Wednesday, November 25, 2009, 1:43am EST - Canadian Markets open in 7 hours and 47 minutes.
To create a watchlist or portfolio of shares, Sign-in or Register

Nephros Inc. (NEP)

 On Nov 24: 5.20 USD  Down 0.01 (0.19%)  
MORE ON NEP
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
CHINA NORTH EAST PET (AMEX:NEP) Delayed quote dataEdit
Last Trade: 5.20 USD
Trade Time: Nov 24
Change: Down 0.01 (0.19%)
Prev Close: 5.21
Open: 5.26
Bid: N/A
Ask: N/A
1y Target Est: 1.50
Day's Range: 5.12 - 5.27
52wk Range: 1.25 - 6.50
Volume: 191,189
Avg Vol (3m): 366,776
Market Cap: 109.14M
P/E (ttm): N/A
EPS (ttm): -0.56
Div & Yield: N/A (N/A%)
Nephros Inc. (NEP)
1d  5d  3m  6m  1y  2y  5y  max 
Free Annual Reports
 Add NEP to Portfolio   Download Data

HEADLINES
• China North East Petroleum Announces Change to its Board of Directors
PRNewswire (Tue 4:01pm)
• CHINA NORTH EAST PETROLEUM HOLDINGS LTD Files SEC form 8-K, Change in Directors or Principal Officers
EDGAR Online (Tue 4:00pm)
• CHINA NORTH EAST PETROLEUM HOLDINGS LTD Financials
EDGAR Online Financials (Thu, Nov 19)
• New Star Analyst Rankings for CHINA NORTH EAST PET
StarMine (Tue, Nov 17)
• China North East Petroleum to Present at Brean Murray 2009 China Growth Conference
PRNewswire (Mon, Nov 16)
• China North East Petroleum Reports Third Quarter 2009 Financial Results
PRNewswire (Mon, Nov 16)
• CHINA NORTH EAST PETROLEUM HOLDINGS LTD Files SEC form 10-Q, Quarterly Report
EDGAR Online (Mon, Nov 16)
• China North East Petroleum Announces Earnings Date and Conference Call for Third Quarter 2009 Financial Results
PRNewswire (Fri, Nov 6)
• China North East Petroleum Announces Preliminary 2009 Third Quarter Oil Production Results
PRNewswire (Tue, Oct 20)
• CHINA NORTH EAST PETROLEUM HOLDINGS LTD Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of
EDGAR Online (Thu, Oct 1)
More Headlines for NEP...
ANALYST
EPS Est (next year) (Dec-07) : N/A
EPS Est (in 2 years) (Dec-08) : N/A
Avg Rec (current)*: N/A
PEG Ratio: N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

BUSINESS SUMMARY
Nephros, Inc. develops end stage renal disease therapy technology and products. The company has three products in various stages of development in the hemodiafiltration (HDF), including OLpur MDHDF filter series, which consist of MD190 and MD220 d...

Full Company Profile

Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
• Latest News • Canadian Indices